Pioglitazone Attenuates Drug-Eluting Stent-Induced Proinflammatory State in Patients by Blocking Ubiquitination of PPAR

Table 2

Metabolic and other parameters at baseline and after 12 weeks.

Parameters	Placebo controls		Pioglitazone
	0 wk	12 wk	0 wk	12 wk
Body mass index, kg/m^2	23.7 ± 4.9	23.3 ± 3.3	24.5 ± 2.9	24.7 ± 2.5
Weight, kg	65.4 ± 12.7	66.7 ± 12.7	68.8 ± 9.4	69.3 ± 8.3
Waist to hip ratio, %	89.1 ± 5.8	89.3 ± 5.6	89.9 ± 5.9	90.2 ± 5.5
Systolic BP, mm Hg	124 ± 19	126 ± 13	121 ± 16	121 ± 15
Diastolic BP, mm Hg	78 ± 10	77 ± 8	76 ± 10	73 ± 9
Fasting glucose, mmol/L	5.28 ± 0.57	5.30 ± 0.49	5.32 ± 0.37	5.31 ± 0.45
Fasting insulin, U/L	6.73 ± 3.98	6.10 ± 4.02	6.79 ± 4.44	5.21 ± 3.62
HbA1c, %	5.42 ± 0.59	5.72 ± 0.46	5.18 ± 0.49	5.79 ± 0.35
Total cholesterol, mmol/L	3.78 ± 0.76	3.12 ± 0.74	3.61 ± 0.45	3.01 ± 0.51
Triglycerides, mmol/L	1.75 ± 1.27	1.38 ± 0.91	1.81 ± 1.23	1.14 ± 0.39
HDL cholesterol, mmol/L	0.90 ± 0.17	1.16 ± 0.41	0.88 ± 0.20	1.27 ± 0.41
LDL cholesterol, mmol/L	2.35 ± 0.67	1.67 ± 0.40	2.15 ± 0.49	1.69 ± 0.40
hsCRP, mg/L	4.0 (0.9, 11.8)	2.2 (0.8, 6.8)	2.9 (1.3, 12.3)	1.0 (0.5, 3.8)
NT-pro BNP, pg/mL	220 (79, 839)	231 (140, 664)	259 (73, 706)	260 (102, 703)
EF, %	61.3 ± 9.9	62.7 ± 9.5	60.4 ± 8.1	60.6 ± 7.4

for each group. Values are mean ± SD or median (interquartile range).
⁢ and compared with baseline, and , compared with the placebo group.